Barbit60 mg

Barbit is a long-acting barbiturate with established anticonvulsant and sedative-hypnotic properties. Its uses are classified below by strength of evidence.

Established / Approved Uses

• Seizure disorders: Long-term management of generalized tonic-clonic (grand mal) and partial (focal) seizures, either alone or in combination with other antiepileptic drugs. It is not effective for absence (petit mal) seizures.
• Status epilepticus: Emergency control of acute convulsive episodes (injectable form), typically after first-line benzodiazepine therapy.
• Neonatal seizures: A first-line agent for neonatal seizure control, particularly in resource-limited settings, due to established efficacy and extensive clinical experience in this age group.
• Sedation: Short-term daytime sedation and pre-operative/pre-anesthetic sedation.
• Short-term treatment of insomnia: Limited to short-term use given its habit-forming potential; generally superseded by safer sedative-hypnotics.

Adjunct / Combination Use

• Used as an adjunct with other antiepileptic drugs when seizures are not adequately controlled on a single agent.
• Historically combined with belladonna alkaloids for functional gastrointestinal disorders; this combination use is now largely outdated.

Off-Label Use

• Management of alcohol or sedative-hypnotic withdrawal syndromes (used off-label in some settings under close medical supervision).
• Adjunct in the management of neonatal hyperbilirubinemia (enzyme induction), used selectively under specialist guidance.

Each tablet/dosage unit contains Phenobarbital as the active ingredient. Phenobarbital is available locally as tablets (30 mg, 60 mg), injection (200 mg/ml), and oral elixir/solution (20 mg/5 ml). Strength and excipients vary by brand and formulation; refer to the specific product label for exact composition.

Barbit is a barbiturate derivative belonging to the older generation of antiepileptic and sedative-hypnotic drugs. Despite the availability of newer antiepileptics, Barbit remains widely used, particularly in resource-limited settings and for neonatal seizure control, due to its proven efficacy, low cost, and long clinical track record.

Barbit depresses the central nervous system (CNS) at all levels, ranging from mild sedation to general anesthesia, depending on dose. It has a narrow therapeutic index relative to some other CNS depressants and a well-recognized potential for physical dependence, tolerance, and abuse, so its use requires careful medical supervision.

Barbit belongs to the barbiturate class of drugs, specifically classified as a long-acting barbiturate anticonvulsant and sedative-hypnotic.

Phenobarbital exerts its effect primarily by enhancing the inhibitory action of gamma-aminobutyric acid (GABA) at the GABA-A receptor. It binds to a distinct barbiturate site on the GABA-A receptor-chloride ionophore complex, increasing the duration of chloride channel opening in response to GABA. This hyperpolarizes the neuronal membrane, reducing neuronal excitability and raising the seizure threshold. At higher doses, Phenobarbital can directly activate chloride channels even without GABA, contributing to its dose-dependent CNS depressant and general anesthetic effects. Phenobarbital also reduces glutamate-induced neuronal excitation at high concentrations.

Phenobarbital is a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP2C9, CYP2C19, and CYP3A4) and UDP-glucuronosyltransferase, which underlies many of its clinically significant drug interactions (see Interactions).

Pharmacokinetics: Phenobarbital is well absorbed orally, with peak plasma levels reached in 1-6 hours. It is 20-45% protein-bound, is metabolized in the liver, and has a long and variable elimination half-life (approximately 53-118 hours in adults, longer in neonates), which allows once- or twice-daily dosing and supports its use as maintenance anticonvulsant therapy. Approximately 25% is excreted unchanged in the urine.

Barbit tablets and oral solution are taken by mouth, with or without food, at the times prescribed. The injectable form is for administration by qualified healthcare professionals only, given the risk of severe respiratory depression with rapid administration. Doses should be taken consistently and never stopped or altered without medical advice, given the risk of withdrawal seizures on abrupt discontinuation.

Barbit is a potent inducer of hepatic CYP450 enzymes, resulting in numerous clinically significant drug interactions:

• Other CNS depressants (opioids, benzodiazepines, alcohol, sedating antihistamines, other sedative-hypnotics): Additive CNS and respiratory depression; this combination carries a serious risk of profound sedation, respiratory depression, coma, and death, and should be avoided or used only with extreme caution and close monitoring.
• Hormonal contraceptives: Barbit induces the metabolism of estrogens and progestins, reducing contraceptive effectiveness and increasing the risk of unintended pregnancy and breakthrough bleeding; alternative or additional non-hormonal contraception is recommended.
• Warfarin and other oral anticoagulants: Barbit reduces anticoagulant effect by increasing warfarin metabolism; dose adjustment and closer INR monitoring are needed when starting or stopping Barbit.
• Other antiepileptic drugs (phenytoin, valproate, carbamazepine, lamotrigine, and others): Complex, often bidirectional interactions affecting serum levels of both drugs; therapeutic drug monitoring is recommended when combined.
• Corticosteroids, doxycycline, and other CYP450 substrates: Barbit can substantially reduce plasma levels and efficacy of these and many other hepatically metabolized drugs.
• MAO inhibitors: May prolong the effects of Barbit; use with caution.
• Valproic acid/sodium valproate: Can increase Barbit serum levels, increasing sedation risk; dose adjustment of Barbit may be needed.

Side effects of Barbit are generally dose-related.

Common

• Drowsiness, sedation, and somnolence
• Dizziness, lightheadedness
• Headache
• Nausea, vomiting
• Cognitive slowing, impaired concentration and memory (especially in children and the elderly)
• Irritability or paradoxical hyperactivity (particularly in children)

Serious (require prompt medical attention)

• Respiratory depression, especially with overdose or combined use with other CNS depressants (see Interactions)
• Severe allergic/hypersensitivity reactions, including angioedema and serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis
• Megaloblastic anemia (with long-term use, related to folate deficiency)
• Osteomalacia/osteoporosis with long-term use (related to altered vitamin D metabolism)
• Physical dependence and withdrawal symptoms on abrupt discontinuation (see Precautions)
• Laryngospasm or hypotension (with rapid intravenous administration)

Pregnancy: Barbit crosses the placenta and has been associated with an increased risk of congenital malformations (including cardiac defects and orofacial clefts) when used during pregnancy, as well as neonatal withdrawal symptoms and hemorrhagic disease of the newborn if used near delivery (vitamin K supplementation is often recommended for the mother and/or neonate in this situation). Barbit should be used in pregnancy only if clearly needed and the potential benefit (e.g., seizure control) justifies the potential risk to the fetus; abrupt discontinuation should be avoided as uncontrolled seizures also carry serious maternal and fetal risk. Use should be individualized and supervised by a physician, ideally with pre-conception counseling in women of childbearing potential.

Lactation: Barbit passes into breast milk and may cause sedation, poor feeding, or withdrawal symptoms in the breastfed infant. Breastfeeding while using Barbit should be discussed with a physician, and infants should be monitored closely for excessive drowsiness or poor weight gain.

Dependence and withdrawal: Prolonged use of Barbit can lead to physical and psychological dependence. Abrupt discontinuation after regular use can precipitate a serious, potentially life-threatening withdrawal syndrome, including withdrawal seizures, anxiety, tremor, insomnia, and, in severe cases, delirium. Barbit must be discontinued only by a gradual, physician-supervised dose taper.

Respiratory depression: Barbit has a comparatively narrow margin between sedative and lethal doses relative to newer sedative-hypnotics, particularly when combined with other CNS depressants such as opioids, benzodiazepines, or alcohol (see Interactions). This combination should be avoided or used only under close medical supervision.

Abuse potential: Barbit is a controlled substance in many jurisdictions due to its potential for abuse and dependence. It should be prescribed and used only as directed, and not shared with others.

Porphyria: See Contraindications - use is contraindicated due to risk of precipitating an acute porphyric attack.

CNS/psychomotor effects: May impair mental alertness and physical coordination; patients should avoid driving or operating hazardous machinery until they know how Barbit affects them.

Elderly patients: May be more sensitive to the sedative and confusional effects of Barbit; lower doses are generally recommended (see Use in Special Populations).

Hepatic/renal impairment: Use with caution and reduced dosing; monitor closely.

Suicidal ideation: As with other antiepileptic drugs, a small increased risk of suicidal thoughts or behavior has been reported; monitor for mood changes, especially early in treatment.

Overdose of Barbit is a medical emergency. Signs and symptoms may include profound CNS depression, drowsiness progressing to coma, confusion, slurred speech, respiratory depression, hypotension, hypothermia, and, in severe cases, cardiovascular collapse and death, particularly when combined with alcohol or other CNS depressants.

If overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away. Do not attempt to treat an overdose at home. Hospital management may include airway support, ventilatory assistance, and other supportive and monitoring measures as determined by treating physicians; specific decontamination or elimination-enhancing measures should only be undertaken by qualified medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Because Barbit is a controlled substance with abuse potential, store it securely away from unauthorized access.

Pregnant Women

Use only if clearly needed; see Pregnancy and Lactation.

Breastfeeding Women

Use with caution and monitor the infant; see Pregnancy and Lactation.

Pediatric Patients

Barbit is well-established for use in children, including neonates, for seizure control, with weight-based dosing (see Dosage and Administration). Children, particularly younger children, may experience paradoxical excitement, irritability, or hyperactivity rather than sedation. Close monitoring of growth, cognitive development, and behavior is recommended with long-term use.

Elderly Patients

Elderly patients are generally more sensitive to the sedative, confusional, and fall-risk effects of Barbit. Lower starting doses and careful titration are recommended, and use for insomnia is generally not recommended in this population due to the availability of safer alternatives.

Renal Impairment

Dose reduction and closer monitoring are recommended, as elimination may be prolonged.

Hepatic Impairment

Barbit is contraindicated in marked hepatic impairment; use with caution and reduced dosing in mild-to-moderate impairment.

Duration of Barbit therapy depends on the indication. For seizure disorders, treatment is typically long-term (often years), guided by seizure control and periodic physician reassessment. For sedation or short-term insomnia, use should be limited to the shortest effective duration (generally days to a few weeks) due to tolerance and dependence risk. Any discontinuation, regardless of indication, must be done gradually under medical supervision to avoid withdrawal seizures.

Barbiturate; anticonvulsant; sedative-hypnotic.

Phenobarbital potentiates GABA-mediated inhibitory neurotransmission by binding to the GABA-A receptor-chloride channel complex, prolonging chloride channel opening and reducing neuronal excitability. At higher concentrations it can directly open chloride channels independent of GABA and also reduces excitatory glutamatergic transmission, producing dose-dependent effects ranging from sedation to anticonvulsant activity to general anesthesia.

Category D (FDA legacy pregnancy category - positive evidence of human fetal risk, but potential benefits may warrant use in certain clinical situations despite the risk)

Barbit is established for use in pediatric patients, including neonates, for the management of seizure disorders, and is considered a first-line anticonvulsant for neonatal seizures in many settings. Dosing is weight-based and should be individualized by a pediatrician or specialist (see Dosage and Administration). Children may be more prone to paradoxical CNS stimulation (irritability, hyperactivity) rather than sedation. Long-term use in children warrants monitoring of growth, cognitive function, and behavior. Safety and efficacy for indications outside of seizure management and sedation have not been well established in pediatric patients, and use for insomnia in children is generally not recommended.